Loading filters...
Publications per Year (4871 total)
22
1990
27
·
25
·
23
·
41
·
45
1995
43
·
42
·
44
·
55
·
46
2000
68
·
63
·
87
·
65
·
117
2005
136
·
127
·
123
·
148
·
141
2010
174
·
174
·
201
·
217
·
203
2015
196
·
209
·
207
·
201
·
221
2020
242
·
241
·
269
·
272
·
259
2025
97
·
Loaded
Click to load
50 / 4871 papers loaded(scroll for more)
202637 papers
GeneralAll Stages2026
Watch-and-Wait Policy to Defer Defunctioning Stoma After Low Anterior Resection: Preliminary Results From the Safe Anastomosis Project (KNUCRC-25CP02).
Kim HJ et al. Dis Colon Rectum. 2026
GeneralEarly (I-III)2026
Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.
Shen Y et al. Clin Cancer Res. 2026
GeneralEarly (I-III)2026
Organ preservation with total neoadjuvant therapy in early-stage rectal cancer: A statewide analysis.
Bunjo Z et al. Colorectal Dis. 2026
MSI-H/dMMRAll Stages2026
Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.
Martin S et al. Br J Cancer. 2026
GeneralEarly (I-III)2026
Late Anastomotic Leakage After Rectal Cancer Surgery: Incidence and Differential Risk Factors.
Kim HK et al. Dis Colon Rectum. 2026
GeneralAll Stages2026
Complications After Rectal Cancer Surgery: Do Female Patients Fare Better? A Retrospective, Matched Cohort Analysis.
Damanakis AI et al. Dis Colon Rectum. 2026
Biomarker/ctDNAEarly (I-III)2026
Preoperative Identification of Lymph Node Metastasis in Colorectal Cancer Using Noninvasive Circulating Tumor DNA Methylation Signatures: Results From a Prospective Study.
Ji H et al. Dis Colon Rectum. 2026
GeneralEarly (I-III)2026
Impact of Obesity on Postoperative Outcomes in Transanal Total Mesorectal Excision for Rectal Cancer.
Zewde MG et al. Dis Colon Rectum. 2026
GeneralAdvanced/Metastatic (IV)2026
eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.
Huang Q et al. Br J Cancer. 2026
GeneralAll Stages2026
A standardised approach to the pathological dissection and reporting of pelvic exenteration specimens: Recommendations from the UK Pelvic Exenteration Network (UKPEN).
Aldridge J et al. Colorectal Dis. 2026
RAS wild-typeAdvanced/Metastatic (IV)2026
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
Gregorc V et al. Lancet Oncol. 2026
GeneralEarly (I-III)2026
Nonoperative Management for Rectal Cancer: A Qualitative Study of Patient Perceptions, Priorities, Barriers, and Facilitators to Surveillance.
Hilty Chu BK et al. Dis Colon Rectum. 2026
GeneralAdvanced/Metastatic (IV)2026
Young adults undergoing anterior resection for colorectal cancer experience fewer medical complications but a comparable risk of anastomotic leak.
Rudasill SE et al. Colorectal Dis. 2026
BRAF V600EAdvanced/Metastatic (IV)2026
Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction.
Funk MA et al. Oncologist. 2026
GeneralEarly (I-III)2026
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Sinicrope FA et al. N Engl J Med. 2026
GeneralAll Stages2026
Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study.
Ghedri A et al. Eur J Cancer. 2026
GeneralAdvanced/Metastatic (IV)2026
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.
Moik F et al. ESMO Open. 2026
GeneralAdvanced/Metastatic (IV)2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
Cecchini M et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic (IV)2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
Kito Y et al. Eur J Cancer. 2026
GeneralEarly (I-III)2026
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer.
Hillson LVS et al. Clin Cancer Res. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.
Yeh C et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic (IV)2026
Distribution and prognostic value of macrophages in colorectal cancer and adjacent mucosa in patient stages I-III vs IV.
Ye WJ et al. World J Gastroenterol. 2026
Biomarker/ctDNAEarly (I-III)2026
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.
Franken IA et al. Eur J Cancer. 2026
MSI-H/dMMRAll Stages2026
Challenges of neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite-unstable localized colon cancer patients.
Karoui M et al. ESMO Open. 2026
GeneralAll Stages2026
Long-term outcomes following a pathological complete response at the primary tumor site after preoperative therapy in metastatic colorectal cancer.
Luo D et al. Oncologist. 2026
RAS mutantAll Stages2026
Emerging landscape of KRAS inhibitors in cancer treatment.
Riedl JM et al. Cancer Cell. 2026
RAS wild-typeAll Stages2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.
Fountzilas C et al. Int J Cancer. 2026
GeneralEarly (I-III)2026
Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.
Noiret B et al. J Clin Oncol. 2026
MSI-H/dMMREarly (I-III)2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.
Yang Z et al. Gut. 2026
HER2 amplifiedAll Stages2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T et al. J Clin Oncol. 2026
RAS wild-typeAdvanced/Metastatic (IV)2026
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.
Keyl J et al. Clin Cancer Res. 2026
MSI-H/dMMRAdvanced/Metastatic (IV)2026
Multiagent Combo Bests Immunotherapy Alone against Colorectal Cancer.
Cancer Discov. 2026
RAS wild-typeAdvanced/Metastatic (IV)2026
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.
Manca P et al. Clin Cancer Res. 2026
GeneralEarly (I-III)2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.
Iveson T et al. J Clin Oncol. 2026
GeneralEarly (I-III)2026
Rectal Cancer in the Elderly: To Operate or Not to Operate? A Nationwide Retrospective Study of the Italian Society of Surgical Oncology-Colorectal Cancer Network Collaborative Group.
Reddavid R et al. Dis Colon Rectum. 2026
GeneralEarly (I-III)2026
Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.
van Megesen K et al. Br J Cancer. 2026
GeneralEarly (I-III)2026
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Tang W et al. J Clin Oncol. 2026
20255 papers
MSI-H/dMMRAll Stages2025
The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study.
Negm L et al. Lancet Oncol. 2025
MSI-H/dMMRAdvanced/Metastatic (IV)2025
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.
André T et al. Ann Oncol. 2025
MSI-H/dMMRAll Stages2025
Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
Poumeaud F et al. Eur J Cancer. 2025
GeneralAll Stages2025
Features of Lateral Pelvic Lymph Nodes Associated With Pathological Involvement After Total Neoadjuvant Therapy in Patients Undergoing Lateral Pelvic Lymph Node Dissection.
Noguchi T et al. Dis Colon Rectum. 2025
GeneralEarly (I-III)2025
Correlation Between Grade of Clinical Response to Neoadjuvant Therapy for Rectal Cancer and Oncologic Outcomes in the Era of Watch-and-Wait.
Rosen RY et al. Dis Colon Rectum. 2025
20248 papers
MSI-H/dMMRAdvanced/Metastatic (IV)2024
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
Margalit O et al. Eur J Cancer. 2024
MSI-H/dMMRAdvanced/Metastatic (IV)2024
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.
Kaviyarasan V et al. Int J Colorectal Dis. 2024
MSI-H/dMMRAll Stages2024
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.
de Gooyer PGM et al. Nat Med. 2024
GeneralAll Stages2024
Tailored resection for persistent extramural vascular invasion in locally advanced rectal cancers.
Ballal DS et al. Colorectal Dis. 2024
MSI-H/dMMRAdvanced/Metastatic (IV)2024
Genomic profiles and their associations with microsatellite instability status, tumor mutational burden, and programmed death ligand 1 expression in Chinese patients with colorectal cancer.
Luo B et al. J Gastrointest Oncol. 2024
MSI-H/dMMRAdvanced/Metastatic (IV)2024
Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability.
Fakih M et al. Oncologist. 2024
MSI-H/dMMRAdvanced/Metastatic (IV)2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T et al. N Engl J Med. 2024
MSI-H/dMMRAll Stages2024
Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status.
Li Y et al. Dis Colon Rectum. 2024